New Monthly GLP-1 Drug Shows 7% Weight Loss in Early Human Trial
MBX 4291, a once-monthly GLP-1/GIP prodrug, delivered 7% average weight loss in 8 weeks with minimal side effects in Phase 1 data.
Summary
MBX Biosciences has released early Phase 1 data for MBX 4291, a new weight-loss drug designed to be taken just once a month. In a small group of participants, the drug produced an average of 7% body weight loss over eight weeks, with some individuals losing up to 16%. Notably, no nausea or vomiting was reported, which is a common complaint with existing GLP-1 drugs like semaglutide. The drug works by activating both GLP-1 and GIP receptors — the same dual mechanism behind tirzepatide — but is formulated as a prodrug that releases slowly, potentially enabling monthly rather than weekly injections. Larger cohort results are expected by late 2026.
Detailed Summary
The obesity drug landscape may be on the verge of another shift. MBX Biosciences has shared preliminary Phase 1 results for MBX 4291, a GLP-1 and GIP receptor co-agonist prodrug designed for once-monthly dosing — a potential convenience upgrade over current weekly injectable standards like semaglutide and tirzepatide.
In the first multiple ascending dose cohort, eight participants (including two on placebo) showed a mean weight loss of 7% over eight weeks, with a range of 0 to 16%. Tolerability appeared favorable: only one subject experienced mild diarrhea, and critically, no nausea or vomiting was reported — side effects that frequently cause patients to reduce or discontinue current GLP-1 therapies.
The pharmacokinetic profile supports the monthly dosing ambition. Single ascending dose data showed the drug reaches peak concentration in roughly 13 to 14 days, and the multiple ascending dose cohort demonstrated an estimated half-life at peak concentration of around 26 days. This slow-release profile is the defining feature of the prodrug design, distinguishing MBX 4291 from faster-acting competitors.
Beyond MBX 4291, the company nominated MBX 5765 as an amycretin prodrug candidate — targeting a broader hormonal pathway — and plans to nominate a triple agonist GLP-1/GIP/glucagon prodrug in Q3 2026. They also reported proof of concept for imapextide in post-bariatric hypoglycemia, a serious complication following weight-loss surgery.
Important caveats apply. The current cohort is very small (n=8), the data remain blinded, and no placebo-adjusted figures have been released. The 12-week Part C readout, expected in Q4 2026, will provide a clearer efficacy picture. These are early-stage results and approval, if it comes, remains years away.
Key Findings
- MBX 4291 produced average 7% weight loss at 8 weeks, with some participants losing up to 16%
- No nausea or vomiting reported, potentially improving tolerability vs. current GLP-1 drugs
- Pharmacokinetic profile supports once-monthly dosing, a major convenience advantage over weekly injectables
- Triple agonist GLP-1/GIP/glucagon candidate also in pipeline, expected nomination Q3 2026
- 12-week efficacy data from a larger cohort expected Q4 2026 for clearer results
Methodology
This is a corporate news report summarizing preliminary, blinded Phase 1 clinical trial data released by MBX Biosciences. The source, Longevity.Technology, is a credible health and longevity news outlet. Evidence is early-stage and based on a very small cohort without published peer-reviewed data.
Study Limitations
The cohort is extremely small (n=8 including two placebo), data remain blinded, and no placebo-adjusted weight loss figures are available. Results are company-reported and not yet peer-reviewed or published. Efficacy and safety at larger scale and longer duration are unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.